GlassScriptPhysician profile
Thiri Khin
NPI 1558797977
$9,422.50
in general payments reported to CMS, 2019-2025
62 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $339 · 2021: $1,130 · 2022: $1,328 · 2023: $2,500 · 2024: $999 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.74 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,506.49 | 2019-2025 | |
| Celgene Corporation | $1,064.31 | 2021-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $614.19 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Pfizer INC. | $527.44 | 2019-2025 | |
| Janssen Biotech, INC. | $510.46 | 2019-2024 | Imbruvica, Darzalex, Tecvayli |
| Incyte Corporation | $355.59 | 2020-2024 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $258.24 | 2019-2025 | Tecentriq, Phesgo, Perjeta |
| Gilead Sciences, INC. | $250.56 | 2021-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $243.99 | 2019-2023 | |
| Amgen INC. | $221.30 | 2019-2022 | |
| Astellas Pharma US INC | $205.97 | 2021-2025 | Padcev, Xospata |
| Daiichi Sankyo INC. | $200.18 | 2020-2025 | Enhertu |
| Eisai INC. | $193.00 | 2019-2024 | |
| Beigene USA, INC. | $187.48 | 2022-2025 | Brukinsa |
| Abbvie INC. | $178.03 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thiri Khin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.